Pharmaceuticals
Pharmaceuticals
Pharmaceuticals overview
Milliman pharmaceuticals insight
Actuarial approaches to modelling and mitigating financial uncertainty in recommending new drugs and health technologies
In collaboration with the National Institute for Health and Care Excellence (NICE) in England, we explore some alternative methodological approaches that build on the incremental cost-effectiveness ratio.
Can we use insurance-based reimbursement models for novel antibiotics?
We explore how the principles of insurance can be applied to structure reimbursement models for novel antibiotics, and ultimately stimulate innovation while offering financial protection to payers.
Evaluating payment models for high-cost curative therapies
A research report that evaluates alternative payment models that potentially could be instituted by healthcare payers and manufacturers to pay for high-cost curative disease therapies and prescription drugs.
Genomic testing: Cost-savings or cost-inflating for payers
The rapid uptake of genetic testing within the National Health Service (NHS) and current debate around genetics make evaluating tailored interventions increasingly more relevant to ensure an efficient use of NHS spend.
U.K.'s NICE sheds light on comparative value
The National Institute for Health and Clinical Excellence in England offers an interesting model for healthcare reform. We asked Joanne Buckle for her perspective.